We are a pharmaceutical company, our facilities are based in Egypt and have 6 Pharmaceutical (Ophthalmology) products almost registered (in the final stages) in Russia and will be in theRussian market in the second half of the year 2022, and looking for a 5 years as well as first quarter of 2022 data analysis depending on Ims data for the segment of Ophthalmology in Russia this data through the mentioned period include at least the following :
- units and value of the total pharmaceutical market.
- units and value of the total Ophthalmology market.
- Percentage of Ophthalmology segment to the total market.
- units and value of the Ophthalmology competitors products ( our 6 products mentioned below) includes Market share , growth, delta growth and Geo share specially Moscow vs total Ophthalmology Russian market .
Other data needed:
- Numbers of ophthalmological hospitals in Moscow,
- Numbers of ophthalmology treatment centers in Moscow,
- Numbers of ophthalmological clinics in Moscow,
Our 6 products:
- Dorzolamid 2,0% + Timolol 0,5%, 5 ml
- Moxifloxacin HCL 5,45 mg (Eg. To Moxifloxacin 5 mg) 10 ml
- Latanoprost 50 mcg
- Tobramycin 0,3%, 5 ml
- Brimonidine Tartarate 2 mg Timolol Maleate 6.8 mg (Eg. to Timolol 5 mg) 5 ml
- Olopatadine 0,1%, 5 ml